Invention Grant
- Patent Title: Determining the capability of a test compound to affect solid tumor stem cells
- Patent Title (中): 测定化合物影响实体瘤干细胞的能力
-
Application No.: US13241701Application Date: 2011-09-23
-
Publication No.: US08420885B2Publication Date: 2013-04-16
- Inventor: Michael F. Clarke , Scott J. Dylla , Sanjeev Satyal
- Applicant: Michael F. Clarke , Scott J. Dylla , Sanjeev Satyal
- Applicant Address: US MI Ann Arbor US CA Redwood City
- Assignee: The Regents of the University of Michigan,Oncomed Pharmaceuticals, Inc.
- Current Assignee: The Regents of the University of Michigan,Oncomed Pharmaceuticals, Inc.
- Current Assignee Address: US MI Ann Arbor US CA Redwood City
- Agency: Casimir Jones, S.C.
- Main IPC: C12Q1/00
- IPC: C12Q1/00 ; G01N33/50 ; C07K14/705 ; C07K16/18 ; A61K39/00

Abstract:
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
Public/Granted literature
- US20120027685A1 DETERMINING THE CAPABILITY OF A TEST COMPOUND TO AFFECT SOLID TUMOR STEM CELLS Public/Granted day:2012-02-02
Information query